{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:48:55Z","timestamp":1760233735911,"version":"build-2065373602"},"reference-count":18,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T00:00:00Z","timestamp":1613260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21198"],"award-info":[{"award-number":["21198"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>Tyrosine kinase inhibitors (TKIs) are the treatment of choice for BCR-ABL1-positive chronic myeloid leukemia (CML). Although TKIs have substantially improved prognosis of CML patients, their use is not free of adverse effects. Dasatinib is a second generation TKI frequently associated with pleural effusion in up to 33% of patients. This results in symptoms as dyspnea, cough and chest pain that may require therapy discontinuation. In the present report, we describe two exceptional cases of HHV8-negative large B-cell effusion-based lymphoma (EBL) confined to the pleura, incidentally, diagnosed in patients presenting with dasatinib-related pleural effusion. One patient (case 1) is alive and is in remission at 17 months from large B-cell EBL diagnosis while unfortunately the other patient (case 2) died of progressive disease and COVID-19 pneumonia 16 months from large B-cell EBL diagnosis. These cases raise concern about a possible association between large B-cell EBL and dasatinib, and the different clinical outcome of the two cases poses a challenge in treatment decision. For this reason, we strongly recommend cytological investigation in patients with persistent\/relapsing pleural effusion under dasatinib, primarily to validate its possible association with lymphoma development and to improve the knowledge about this entity.<\/jats:p>","DOI":"10.3390\/biology10020152","type":"journal-article","created":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T08:53:56Z","timestamp":1613292836000},"page":"152","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["HHV8-Negative Effusion-Based Large B Cell Lymphoma Arising in Chronic Myeloid Leukemia Patients under Dasatinib Treatment: A Report of Two Cases"],"prefix":"10.3390","volume":"10","author":[{"given":"Stefano","family":"Fiori","sequence":"first","affiliation":[{"name":"Division of Diagnostic Hematopathology, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Todisco","sequence":"additional","affiliation":[{"name":"Division of Onco-Hematology, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safaa","family":"Ramadan","sequence":"additional","affiliation":[{"name":"Division of Onco-Hematology, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy"},{"name":"Department of Medical Oncology, NCI-Cairo University, Kasr Al Eini Street, 11796 Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Gigli","sequence":"additional","affiliation":[{"name":"Division of Onco-Hematology, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Falco","sequence":"additional","affiliation":[{"name":"SSD Ematologia, ASLTO4, Ospedali di Chivasso Ciri\u00e9 Ivrea, TO10034 Chivasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-0812","authenticated-orcid":false,"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[{"name":"Division of Hematology, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiano","family":"Rampinelli","sequence":"additional","affiliation":[{"name":"Division of Medical Imaging and Radiation Sciences, IEO, European Institute of Oncology, IRCSS, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Croci","sequence":"additional","affiliation":[{"name":"Division of Pathology, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8032-5128","authenticated-orcid":false,"given":"Stefano A.","family":"Pileri","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Hematopathology, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Tarella","sequence":"additional","affiliation":[{"name":"Division of Onco-Hematology, European Institute of Oncology, IRCCS, Via Ripamonti 435, 20141 Milan, Italy"},{"name":"Dipartimento Universitario di Scienze della Salute (DISS), Universita\u2019 di Milano, 20133 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3324\/haematol.2018.188987","article-title":"Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia","volume":"104","author":"Hughes","year":"2019","journal-title":"Haematologica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","article-title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","volume":"123","author":"Kantarjian","year":"2014","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/leu.2016.20","article-title":"Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: Long-term observation in CML Study IV","volume":"30","author":"Miranda","year":"2016","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.2147\/OTT.S212838","article-title":"A case of primary gastric diffuse large B-cell lymphoma occurring in chronic myeloid leukemia","volume":"12","author":"Cai","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1182\/blood-2003-07-2436","article-title":"EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate","volume":"102","author":"Bekkenk","year":"2003","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/sj.leu.2404758","article-title":"EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia","volume":"21","author":"Leguay","year":"2007","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.3324\/haematol.2019.217141","article-title":"Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia","volume":"104","author":"Yamaguchi","year":"2019","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","article-title":"Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia","volume":"94","author":"Kim","year":"2009","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/PAS.0000000000000488","article-title":"Dasatinib-related follicular hyperplasia: An underrecognized entity with characteristic morphology","volume":"39","author":"Ozawa","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3389\/fphar.2019.01340","article-title":"Immediate effects of dasatinib on the migration and redistribution of na\u00efve and memory lymphocytes associated with lymphocytosis in chronic myeloid leukemia patients","volume":"10","author":"Kreutzman","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_12","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). EBV-positive mucocutaneous ulcer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC. [4th ed.]."},{"key":"ref_13","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). Post-transplant lymphoproliferative disorders. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC. [4th ed.]."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1182\/bloodadvances.2020002293","article-title":"Primary human herpesvirus 8-negative effusion-based lymphoma: A large B-cell lymphoma with favorable prognosis","volume":"4","author":"Kaji","year":"2020","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3960\/jslrt.17020","article-title":"Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia","volume":"57","author":"Kojima","year":"2017","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/cyt.12890","article-title":"Dasatinib-related effusion lymphoma in a patient treated for chronic myeloid leukaemia","volume":"31","author":"Miyagi","year":"2020","journal-title":"Cytopathology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/PAS.0b013e318267fabc","article-title":"KSHV\/HHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states","volume":"37","author":"Alexanian","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/PAS.0000000000000775","article-title":"Fibrin-associated EBV-positive large B-cell lymphoma","volume":"41","author":"Boyer","year":"2017","journal-title":"Am. J. Surg. Pathol."}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/10\/2\/152\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:24:08Z","timestamp":1760160248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/10\/2\/152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,14]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["biology10020152"],"URL":"https:\/\/doi.org\/10.3390\/biology10020152","relation":{},"ISSN":["2079-7737"],"issn-type":[{"type":"electronic","value":"2079-7737"}],"subject":[],"published":{"date-parts":[[2021,2,14]]}}}